165 related articles for article (PubMed ID: 21751235)
1. Neuroimmunomodulative properties of dipeptidyl peptidase IV/CD26 in a TNBS-induced model of colitis in mice.
Baticic L; Detel D; Kucic N; Buljevic S; Pugel EP; Varljen J
J Cell Biochem; 2011 Nov; 112(11):3322-33. PubMed ID: 21751235
[TBL] [Abstract][Full Text] [Related]
2. Development and resolution of colitis in mice with target deletion of dipeptidyl peptidase IV.
Detel D; Pugel EP; Pucar LB; Buljevic S; Varljen J
Exp Physiol; 2012 Apr; 97(4):486-96. PubMed ID: 22125312
[TBL] [Abstract][Full Text] [Related]
3. Influence of CD26/dipeptidyl peptidase IV deficiency on immunophenotypic changes during colitis development and resolution.
Detel D; Buljevic S; Pucar LB; Kucic N; Pugel EP; Varljen J
J Physiol Biochem; 2016 Sep; 72(3):405-19. PubMed ID: 27125676
[TBL] [Abstract][Full Text] [Related]
4. Levels of dipeptidyl peptidase IV/CD26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients.
Buljevic S; Detel D; Pucar LB; Mihelic R; Madarevic T; Sestan B; Varljen J
Rheumatol Int; 2013 Nov; 33(11):2867-74. PubMed ID: 23864142
[TBL] [Abstract][Full Text] [Related]
5. A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice.
Sun X; Somada S; Shibata K; Muta H; Yamada H; Yoshihara H; Honda K; Nakamura K; Takayanagi R; Tani K; Podack ER; Yoshikai Y
Gastroenterology; 2008 Feb; 134(2):447-58. PubMed ID: 18242212
[TBL] [Abstract][Full Text] [Related]
6. Regulation of gut inflammation and th17 cell response by interleukin-21.
Fina D; Sarra M; Fantini MC; Rizzo A; Caruso R; Caprioli F; Stolfi C; Cardolini I; Dottori M; Boirivant M; Pallone F; Macdonald TT; Monteleone G
Gastroenterology; 2008 Apr; 134(4):1038-48. PubMed ID: 18395085
[TBL] [Abstract][Full Text] [Related]
7. The effect of CD26-deficiency on dipeptidyl peptidase 8 and 9 expression profiles in a mouse model of Crohn's disease.
Buljevic S; Detel D; Pugel EP; Varljen J
J Cell Biochem; 2018 Aug; 119(8):6743-6755. PubMed ID: 29693275
[TBL] [Abstract][Full Text] [Related]
8. VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis.
Yadav M; Huang MC; Goetzl EJ
Cell Immunol; 2011; 267(2):124-32. PubMed ID: 21295288
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease.
Abad C; Martinez C; Juarranz MG; Arranz A; Leceta J; Delgado M; Gomariz RP
Gastroenterology; 2003 Apr; 124(4):961-71. PubMed ID: 12671893
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase IV (DPP4)-deficiency attenuates diet-induced obesity in rats: possible implications for the hypothalamic neuropeptidergic system.
Stephan M; Radicke A; Leutloff S; Schmiedl A; Pabst R; von Hörsten S; Dettmer S; Lotz J; Nave H
Behav Brain Res; 2011 Jan; 216(2):712-8. PubMed ID: 20887754
[TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal peptide-deficient mice exhibit reduced pathology in trinitrobenzene sulfonic acid-induced colitis.
Abad C; Cheung-Lau G; Coûté-Monvoisin AC; Waschek JA
Neuroimmunomodulation; 2015; 22(3):203-12. PubMed ID: 25301381
[TBL] [Abstract][Full Text] [Related]
12. Preventive effects of Schistosoma japonicum ova on trinitrobenzenesulfonic acid-induced colitis and bacterial translocation in mice.
Zhao Y; Zhang S; Jiang L; Jiang J; Liu H
J Gastroenterol Hepatol; 2009 Nov; 24(11):1775-80. PubMed ID: 20136961
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase IV (DPP4) deficiency increases Th1-driven allergic contact dermatitis.
Tasic T; Bäumer W; Schmiedl A; Schwichtenhövel F; Pabst R; Raap U; von Hörsten S; Stephan M
Clin Exp Allergy; 2011 Aug; 41(8):1098-107. PubMed ID: 21672052
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase IV in the hypothalamus and hippocampus of monosodium glutamate obese and food-deprived rats.
Alponti RF; Frezzatti R; Barone JM; Alegre Vde S; Silveira PF
Metabolism; 2011 Feb; 60(2):234-42. PubMed ID: 20153005
[TBL] [Abstract][Full Text] [Related]
15. Mice lacking cannabinoid CB1-, CB2-receptors or both receptors show increased susceptibility to trinitrobenzene sulfonic acid (TNBS)-induced colitis.
Engel MA; Kellermann CA; Burnat G; Hahn EG; Rau T; Konturek PC
J Physiol Pharmacol; 2010 Feb; 61(1):89-97. PubMed ID: 20228420
[TBL] [Abstract][Full Text] [Related]
16. Protease-activated receptor-2 activation: a major actor in intestinal inflammation.
Hyun E; Andrade-Gordon P; Steinhoff M; Vergnolle N
Gut; 2008 Sep; 57(9):1222-9. PubMed ID: 18460552
[TBL] [Abstract][Full Text] [Related]
17. [Dipeptidyl peptidase IV in inflammatory bowel diseases (DPP IV/CD26)].
Pučar LB; Detel D; Varljen J
Arh Hig Rada Toksikol; 2012 Mar; 63(1):75-100. PubMed ID: 22450208
[TBL] [Abstract][Full Text] [Related]
18. Circulating CD26 is negatively associated with inflammation in human and experimental arthritis.
Busso N; Wagtmann N; Herling C; Chobaz-Péclat V; Bischof-Delaloye A; So A; Grouzmann E
Am J Pathol; 2005 Feb; 166(2):433-42. PubMed ID: 15681827
[TBL] [Abstract][Full Text] [Related]
19. The DPP-IV inhibitor ER-319711 has a proliferative effect on the colonic epithelium and a minimal effect in the amelioration of colitis.
Ban H; Bamba S; Imaeda H; Inatomi O; Kobori A; Sasaki M; Tsujikawa T; Andoh A; Fujiyama Y
Oncol Rep; 2011 Jun; 25(6):1699-703. PubMed ID: 21431278
[TBL] [Abstract][Full Text] [Related]
20. Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion.
Lambeir AM; Durinx C; Proost P; Van Damme J; Scharpé S; De Meester I
FEBS Lett; 2001 Nov; 507(3):327-30. PubMed ID: 11696365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
